Log in Sign up
Trending
CFPs: Alzheimer’s Research Grant Programme (UK) is trending now Drug-resistant gonorrhea on the rise in Europe, ECDC warns is trending now WHO Urges Africa To Break Barriers To Hepatitis Care is trending now Environmental changes help spread lassa fever in West Africa – Expert is trending now Carbon nanotube model reveals how smart sensors perform at aircraft-like extremes is trending now Molecules stop carbon nanotubes clumping, unlocking record heat-to-electricity performance is trending now New cell imaging method measures protein folding in living organelles is trending now Scientists discover mystery molecule on Pluto and Saturn's moon Titan: 'We cannot say wha… is trending now Chelsea step up interest in Palace's Lacroix is trending now A cavalcade of international stars headlined the World Cup’s first-ever halftime final sh… is trending now Spain’s World Cup Heroes Return Home Ahead Of Victory Parade is trending now Argentina FA president pays tribute to Lionel Messi: 'A story that will live forever' is trending now CFPs: Alzheimer’s Research Grant Programme (UK) is trending now Drug-resistant gonorrhea on the rise in Europe, ECDC warns is trending now WHO Urges Africa To Break Barriers To Hepatitis Care is trending now Environmental changes help spread lassa fever in West Africa – Expert is trending now Carbon nanotube model reveals how smart sensors perform at aircraft-like extremes is trending now Molecules stop carbon nanotubes clumping, unlocking record heat-to-electricity performance is trending now New cell imaging method measures protein folding in living organelles is trending now Scientists discover mystery molecule on Pluto and Saturn's moon Titan: 'We cannot say wha… is trending now Chelsea step up interest in Palace's Lacroix is trending now A cavalcade of international stars headlined the World Cup’s first-ever halftime final sh… is trending now Spain’s World Cup Heroes Return Home Ahead Of Victory Parade is trending now Argentina FA president pays tribute to Lionel Messi: 'A story that will live forever' is trending now
Health

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal

M MedCity News · · 69 views

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. The post Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal appeared first on MedCity News.

View original source →

Related

More from MedCity News